Cencora Inc. (COR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Cencora Inc. (COR) has a cash flow conversion efficiency ratio of 0.373x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.34 Billion) by net assets ($3.58 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Cencora Inc. (COR) liquidity interval to measure how many days the company can operate on defensive assets alone.
Cencora Inc. - Cash Flow Conversion Efficiency Trend (1994–2025)
This chart illustrates how Cencora Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Cencora Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Cencora Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Electronic Arts Inc
NASDAQ:EA
|
0.086x |
|
Ambev S.A
MX:ABEVN
|
0.075x |
|
Arthur J Gallagher & Co
NYSE:AJG
|
0.040x |
|
Wal-Mart de México S.A.B. de C.V
MX:WALMEX
|
0.020x |
|
Rockwell Automation Inc
NYSE:ROK
|
0.089x |
|
AutoZone Inc
NYSE:AZO
|
-0.128x |
|
HOYA CORP. ADR/ 1 O.N.
F:HYB0
|
N/A |
|
Discover Financial Services
NYSE:DFS
|
0.112x |
Annual Cash Flow Conversion Efficiency for Cencora Inc. (1994–2025)
The table below shows the annual cash flow conversion efficiency of Cencora Inc. from 1994 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Cencora Inc. worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $1.75 Billion | $3.88 Billion | 2.218x | -49.92% |
| 2024-09-30 | $786.74 Million | $3.48 Billion | 4.429x | -24.55% |
| 2023-09-30 | $666.29 Million | $3.91 Billion | 5.870x | -84.52% |
| 2022-09-30 | $71.27 Million | $2.70 Billion | 37.926x | +731.19% |
| 2021-09-30 | $584.41 Million | $2.67 Billion | 4.563x | +273.59% |
| 2020-09-30 | $-839.64 Million | $2.21 Billion | -2.629x | -403.40% |
| 2019-09-30 | $2.71 Billion | $2.34 Billion | 0.866x | +65.84% |
| 2018-09-30 | $2.70 Billion | $1.41 Billion | 0.522x | -27.57% |
| 2017-09-30 | $2.06 Billion | $1.49 Billion | 0.721x | -52.77% |
| 2016-09-30 | $2.08 Billion | $3.18 Billion | 1.527x | -84.83% |
| 2015-09-30 | $389.56 Million | $3.92 Billion | 10.064x | +1245.96% |
| 2014-09-30 | $1.96 Billion | $1.46 Billion | 0.748x | +120.07% |
| 2013-09-30 | $2.32 Billion | $788.12 Million | 0.340x | -36.06% |
| 2012-09-30 | $2.46 Billion | $1.31 Billion | 0.531x | +30.43% |
| 2011-09-30 | $2.87 Billion | $1.17 Billion | 0.407x | +8.56% |
| 2010-09-30 | $2.95 Billion | $1.11 Billion | 0.375x | +30.06% |
| 2009-09-30 | $2.72 Billion | $783.76 Million | 0.289x | +6.08% |
| 2008-09-30 | $2.71 Billion | $737.07 Million | 0.272x | -30.21% |
| 2007-09-30 | $3.10 Billion | $1.21 Billion | 0.390x | +99.90% |
| 2006-09-30 | $4.14 Billion | $807.26 Million | 0.195x | -45.34% |
| 2005-09-30 | $4.28 Billion | $1.53 Billion | 0.357x | +87.57% |
| 2004-09-30 | $4.34 Billion | $825.08 Million | 0.190x | +114.65% |
| 2003-09-30 | $4.01 Billion | $354.81 Million | 0.089x | -45.18% |
| 2002-09-30 | $3.32 Billion | $535.93 Million | 0.162x | +1246.68% |
| 2001-09-30 | $2.84 Billion | $-40.00 Million | -0.014x | -101.84% |
| 2000-09-30 | $282.29 Million | $216.58 Million | 0.767x | +4152.92% |
| 1999-09-30 | $166.30 Million | $3.00 Million | 0.018x | -98.92% |
| 1998-09-30 | $75.30 Million | $125.90 Million | 1.672x | +357.09% |
| 1997-09-30 | $14.30 Million | $-9.30 Million | -0.650x | +40.17% |
| 1996-09-30 | $-36.80 Million | $40.00 Million | -1.087x | -514.33% |
| 1995-09-30 | $-135.70 Million | $-35.60 Million | 0.262x | +193.91% |
| 1994-09-30 | $-300.70 Million | $84.00 Million | -0.279x | -- |
About Cencora Inc.
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order … Read more